Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Immune Therapeutics, Inc. (IMUN)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 | Mar-31-21 |
| | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q |
| Revenues | | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of goods sold | | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% |
| Gross profit | | 0.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 0.0% |
| Selling, general and administrative | | 520757.0% | -24.6% | -23.3% | | -25.3% | 234.5% | 1009858.5% |
| Research and development | | | | | | | 84.3% | 459324.5% |
| General and administrative | | | | | -5.5% | | | |
| EBIT | | 62606.0% | 89.4% | 91.4% | 139.1% | 146.0% | -282.4% | -1470088.7% |
| Pre-tax income | | -1730881.5% | -71.7% | -8.9% | -133.2% | -107.0% | 1296.2% | 5984705.7% |
| Income taxes | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | | -1730881.5% | -71.7% | -8.9% | -133.2% | -107.0% | 1296.2% | 5984705.7% |
|